{"product_id":"dhfr-in-9-bhb20444100","title":"DHFR-IN-9","description":"\u003cstyle\u003e\n.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}\n.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}\n.bhp-desc p{margin:0 0 12px}\n.bhp-desc .bhp-spec-table{width:100%;border-collapse:collapse;margin:12px 0 18px}\n.bhp-desc .bhp-spec-table th{width:36%;text-align:left;padding:8px 12px;background:#e8f0fb;color:#003366;font-weight:600;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-spec-table td{padding:8px 12px;vertical-align:top;border:1px solid #ccd9f0}\n.bhp-desc .bhp-warning-box{background:#fff8e6;border-left:4px solid #e6a817;padding:10px 14px;margin:10px 0 14px;border-radius:0 4px 4px 0}\n\u003c\/style\u003e\n\u003cdiv class=\"bhp-desc\"\u003e\n  \u003ch2\u003eCompound Overview\u003c\/h2\u003e\n  \u003cp\u003e\u003cstrong\u003eDHFR-IN-9\u003c\/strong\u003e is a research-grade small molecule supplied by TargetMol.\u003c\/p\u003e\n\n  \u003ch2\u003ePhysical Properties\u003c\/h2\u003e\n  \u003ctable class=\"bhp-spec-table\"\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Formula\u003c\/th\u003e\n\u003ctd\u003eC19H16N6S\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eMolecular Weight\u003c\/th\u003e\n\u003ctd\u003e360.44 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eForm\u003c\/th\u003e\n\u003ctd\u003eSolid\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003cth\u003eShipping\u003c\/th\u003e\n\u003ctd\u003eRoom Temperature (RT)\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/table\u003e\n  \u003ch2\u003eBiological Activity\u003c\/h2\u003e\n  \u003cp\u003eDHFR-IN-9 (compound 8A), a dihydrofolate reductase (DHFR) inhibitor, impedes purine and thymidylate biosynthesis, pivotal in cell proliferation and growth. It demonstrates potency against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 with an IC50 of 0.25 ug\/mL and exhibits anti-infective properties in mouse systemic and thigh infection models at doses of 2.5 mg\/kg and 5 mg\/kg administered intraperitoneally (ip). Furthermore, DHFR-IN-9 shows greater anticancer efficacy in a mouse breast cancer model compared to paclitaxel (Y-B0015), at a regimented dosage of 2.5 mg\/kg ip every three days (1).\u003c\/p\u003e\n  \u003ch2\u003eSafety \u0026amp; Regulatory\u003c\/h2\u003e\n  \u003cdiv class=\"bhp-warning-box\"\u003e\n    \u003cp\u003e\u003cstrong\u003eFor Research Use Only (RUO).\u003c\/strong\u003e Not for therapeutic, diagnostic, or clinical use. Wear appropriate PPE and consult the Safety Data Sheet (SDS) prior to handling.\u003c\/p\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"TargetMol","offers":[{"title":"5 mg","offer_id":53327279685997,"sku":"T79735-5MG","price":0.0,"currency_code":"USD","in_stock":true},{"title":"50 mg","offer_id":53327555527021,"sku":"T79735-50MG","price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/dhfr-in-9-bhb20444100","provider":"BioHippo","version":"1.0","type":"link"}